Trial Profile
Phase 2 Study of Enzalutamide and GnRH Agonist Before, During and After Radiation Therapy in Treatment of Patients With High-risk Localized Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 17 Sep 2020 Status changed from active, no longer recruiting to completed.
- 13 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 13 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.